Cervical Cancer clinical trials
Showing 151–186 of 186 active trials. Describe your situation to see which ones you may be eligible for.
- Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance Therapy
- Improving Care for Rural Patients With Solid Tumors
- Oral 5 Strain Probiotic for GI Toxicity Mitigation During Pelvic Radiation
- Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials
- Physical Activity Intervention Among Older Women With Gynecologic Cancers (Fit4Treatment)
- Pre-Rehabilitation for Female Patients Undergoing Pelvic Radiotherapy
- Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer
- A Study of CS231295 in Patients With Advanced Solid Tumors
- A Mobile Web App Intervention to Promote Cervical Cancer Screening
- Testing for Safety and Immune Effects of PDS0101, an Anti-HPV Therapy, Among People Living With HIV
- Developing and Implementing HPV SCREENED
- Effectiveness of an EHealth Intervention for Uptake of Cervical Cancer Screening in Hispanic Women
- RISE: Reducing Cancer and HIV Stigma Through Empowerment
- Self-Collection for Cervical Cancer Screening and HPV Vaccination for Cancer Prevention Among Women in Emergency Care in Northeast Florida
- C-3002: Enhancing Cervical Cancer Screening Access and Follow-up Care at 'CASCADE' Clinical Sites in the United States
- COQ10 and Vitamin E for Off-Target Radiation Toxicity
- Flyte Device for Improving Urinary Incontinence Among Endometrial and Cervical Cancer Survivors Who Have Undergone Radiation Therapy
- Feasibility of Addressing Sexual Dysfunction in Women with Breast and Gynecologic Cancers with a Novel Mobile Application
- The Use of the LuViva Advanced Cervical Scan to Identify Women at High-Risk for Cervical Neoplasia
- HPV Self-sampling to Improve Access to Cervical Cancer Screening for Persons With HIV and/or Underserved Individuals
- Offering HPV Self-Collection in Novel Healthcare Settings to Improve Uptake of Cervical Cancer Screening
- Accelerating the Implementation of a Breast and Cervical Cancer Screening and HPV Vaccination Intervention
- A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4
- A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)
- Identifying and Addressing Barriers to Retention in the Cervical Cancer Treatment Cascade Among Women With HIV in South Africa: Part 2
- Study of NEO-201 in Solid Tumors Expansion Cohorts
- A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01)
- A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab
- A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors
- Hugo™ Robotic-Assisted Surgery (RAS) System in Gynecological Subjects (Embrace Gynecology)
- Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors
- Evaluating Innovative Technologies and Approaches to Addressing Cervical Cancer in Gaza and Maputo Cidade Provinces in Mozambique
- Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers
- Social Health, Activity Behaviors, and Quality of Life Among Young Adult Cancer Survivors
- Ovarian-Sparing Adaptive Radiotherapy in Young Adult Women
- Time-Restricted Eating Versus Nutritional Counseling for the Reduction of Radiation or Chemoradiation Tx Side Effects in Patients With Prostate, Cervical, or Rectal Cancers
Guides for people searching for a trial
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.